Citigroup Maintains Buy on Faeth Therapeutics, Raises Price Target to $60
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Geoff Meacham maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and raises the price target from $55 to $60.
Citigroup analyst Geoff Meacham maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and raises the price target from $55 to $60.